Shirin Khambata-Ford

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi request reprint Responsiveness to cetuximab without mutations in EGFR
    Zenta Tsuchihashi
    N Engl J Med 353:208-9. 2005
  2. ncbi request reprint Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
    Shirin Khambata-Ford
    Bristol Myers Squibb Co, Princeton, NJ 08543, USA
    J Clin Oncol 25:3230-7. 2007
  3. doi request reprint Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer
    Shirin Khambata-Ford
    Bristol Myers Squibb, 311 Pennington Rocky Hill Rd, 3B 2 06, Princeton, NJ 08543, USA
    J Clin Oncol 28:918-27. 2010
  4. doi request reprint Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial
    Christopher T Harbison
    Bristol Myers Squibb, Rte 206 and Province Line Rd, Princeton, NJ 08543, USA
    Arch Pathol Lab Med 137:820-7. 2013
  5. doi request reprint Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer
    Fei Huang
    Bristol Myers Squibb Co, Route 206 and Province Line Rd, Room E1 293, Princeton, NJ 08453, USA
    Clin Cancer Res 18:1156-66. 2012
  6. ncbi request reprint Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Heinz Josef Lenz
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    J Clin Oncol 24:4914-21. 2006
  7. doi request reprint K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
  8. pmc Identification of promoter regions in the human genome by using a retroviral plasmid library-based functional reporter gene assay
    Shirin Khambata-Ford
    Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA
    Genome Res 13:1765-74. 2003

Detail Information

Publications8

  1. ncbi request reprint Responsiveness to cetuximab without mutations in EGFR
    Zenta Tsuchihashi
    N Engl J Med 353:208-9. 2005
  2. ncbi request reprint Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
    Shirin Khambata-Ford
    Bristol Myers Squibb Co, Princeton, NJ 08543, USA
    J Clin Oncol 25:3230-7. 2007
    ..This study was conducted to identify markers that are associated with disease control in patients treated with cetuximab...
  3. doi request reprint Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer
    Shirin Khambata-Ford
    Bristol Myers Squibb, 311 Pennington Rocky Hill Rd, 3B 2 06, Princeton, NJ 08543, USA
    J Clin Oncol 28:918-27. 2010
    ..Additional exploratory analyses are essential to identify predictive markers and to optimize patient selection for cetuximab therapy in NSCLC...
  4. doi request reprint Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial
    Christopher T Harbison
    Bristol Myers Squibb, Rte 206 and Province Line Rd, Princeton, NJ 08543, USA
    Arch Pathol Lab Med 137:820-7. 2013
    ....
  5. doi request reprint Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer
    Fei Huang
    Bristol Myers Squibb Co, Route 206 and Province Line Rd, Room E1 293, Princeton, NJ 08453, USA
    Clin Cancer Res 18:1156-66. 2012
    ....
  6. ncbi request reprint Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Heinz Josef Lenz
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
    J Clin Oncol 24:4914-21. 2006
    ..It also evaluated the safety, pharmacokinetics, immunokinetics, and biologic determinants of activity...
  7. doi request reprint K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
    ..The mutation status of the K-ras gene in the tumor may affect the response to cetuximab and have treatment-independent prognostic value...
  8. pmc Identification of promoter regions in the human genome by using a retroviral plasmid library-based functional reporter gene assay
    Shirin Khambata-Ford
    Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA
    Genome Res 13:1765-74. 2003
    ..This method promises to be a useful genome-wide function-based approach that can complement existing methods to look for promoters...